Navigation Links
FDA Commissioner announces Avastin decision
Date:11/18/2011

day hearing held in June, 2011.

Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. The accelerated approval program provides earlier patient access to promising new drugs to treat serious or life-threatening conditions while confirmatory clinical trials are conducted. If the clinical trials do not justify the continued approval of the drug or a specific drug indication, the agency may revoke its approval. In this case, the accelerated approval was based on promising results from one study that suggested that the drug could provide a meaningful increase in the amount of time from when treatment is started until the tumor grows or the death of the patient.

After the accelerated approval of Avastin for breast cancer, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone – not enough to outweigh the risk of taking the drug.  

FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.  

Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, 2011, included recommendations from the FDA's Oncologic Drugs Advisory Committee (ODAC), voting 6-0 in favor of withdrawing approval of
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New York City Mayor Bloomberg and Health Commissioner Farley Receive Flu Shot at Duane Reade Pharmacy, Highlight Importance of Flu Preparedness
2. FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans
3. NORD Hosts Forum for FDA Commissioner and Patient Leaders
4. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
5. AdvaMed 2010 Premier Medical Technology Conference Opens Today in Washington D.C. With Executive Workshops, Company Presentations, Innovation Alley Exhibits and Featured Keynote Speakers: FDA Commissioner Dr. Margaret Hamburg, CMS Administrator Dr.
6. Medical Device Conference Opens October 18, 2010 With Free Executive Workshops; Full Conference Highlights Latest Industry Trends, Technology Innovations and Keynote Speeches by the U.S. FDA Commissioner, U.S. CMS Administrator, CBS Evening News Anc
7. Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process
8. EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia
9. Nonin Medical Announces Launch of Worlds First and Only OEM Solution for Regional Oximetry at Medica Congress
10. Disposable Film Festival Health Announces 2011 Award Winners
11. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015  The first national study ... supplements to treat attention-deficit/hyperactivity disorder (ADHD) among children ... of children with ADHD were receiving behavioral therapy ... Control and Prevention (CDC) study, "Treatment of Attention-Deficit/Hyperactivity ... published today in The Journal of Pediatrics ...
(Date:4/1/2015)... 31, 2015 Research and Markets ... the "Metabolic Testing Market by Product (CPET, ... (Critical Care, Lifestyle Diseases), by Technology (REE, Body ... - Global Forecast to 2019 " report ... testing market is expected to reach $475.75 million ...
(Date:4/1/2015)... -- The fairness of the proposed acquisition of Auspex Pharmaceuticals ... ("Teva") is being investigated by WeissLaw LLP, a national ... on possible breaches of fiduciary duty and other violations ... for agreeing to sell the Company to Teva.  On ... for Teva to acquire ASPX in a transaction valued ...
Breaking Medicine Technology:CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4Global Metabolic Testing (CPET, Body Composition Analysis, ECG, Portable System) Market 2015-2019 - REE, Body Composition Analysis for Gyms, Sports & Hospital 2WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Neogen Corporation (Nasdaq: NEOG ) announces the ... Results WebcastWhen: , Thursday, September 23, 2010  @ 11:00 ... over the Internet -- Simply log on to the web ... Neogen Corporation, +1-800-234-5333.If you are unable to participate during the ...
... FORD, Pa., Sept. 22 Endo Pharmaceuticals (Nasdaq: ... U.S. Food and Drug Administration (FDA) that Endo,s new drug ... which is designed to be crush resistant, has been granted ... under the Prescription Drug User Fee Act (PDUFA) for Jan. ...
Cached Medicine Technology:
(Date:4/2/2015)... FL (PRWEB) April 02, 2015 As ... and Field gets its start! Runners have been putting ... ready to start racing. Zensah®, a premium compression apparel ... help ensure the athletes are benefiting from compression ... Zensah® is a Miami-based company, committed to using the ...
(Date:4/2/2015)... Oregon (PRWEB) April 02, 2015 ... sweeteners and custom sweetening solutions, recently announced the ... portfolio are Erysweet+ with stevia and Erysweet+ 100 ... and Stevia Blend fine powder, respectively. , Erysweet+ ... 95-60 and naturally fermented erythritol. It delivers a ...
(Date:4/1/2015)... BMA Management, a leader in assisted living ... to Gardant Management Solutions this spring. , “The name ... of our company and mirrors the optimistic, forward-looking focus ... we see,” said Rod Burkett, President and CEO of ... the company remains committed to providing a dignified, enriched ...
(Date:4/1/2015)... Royal River Natural Foods, a locally-owned independent natural ... found the amino acid creatine, which athletes typically use to ... pressure. , The report is part of the ... ,” which Royal River Natural Foods publishes each month as ... the latest in nutrition science. Also in the April issue, ...
(Date:4/1/2015)... panel session will look at the need for insurance ... that can grow in a privacy-friendly manner, thus preventing ... This topic has taken on even greater relevance in ... aren’t as secure as the automobile industry thought they ... Snapshot dongles contained very significant security flaws, which allowed ...
Breaking Medicine News(10 mins):Health News:Zensah® Partners With Austin Track Club 2Health News:Zensah® Partners With Austin Track Club 3Health News:Steviva Ingredients Announces Erysweet+ Rebrand 2Health News:New Study Finds Strength-Building Supplement Improves Circulation, Retailer Reports 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3
... arthritic symptoms so severe that some victims can,t even walk. ... last up to a year., More than two million people ... Most of the infections have occurred in Southeast Asia, but ... likely because of global travel., With no vaccine available for ...
... Goodwin HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) ... U.S. population -- live in areas where the air is so ... says. Residents of Honolulu and Santa Fe-Espanola, N.M., on the ... is among the country,s cleanest -- and they were the only ...
... An experimental new drug that may treat hepatitis C more ... panel of experts for the U.S. Food and Drug Administration. ... be prescribed in combination with two existing drugs to help ... damage, according to documents posted by the FDA on its ...
... Serena Gordon HealthDay Reporter , TUESDAY, April 26 ... leaves the house, Nancy Geller worries about the food her ... allergy, and exposure to even a small amount of a ... "It,s a big worry, especially now that she,s a teenager ...
... cycles, known as circadian rhythms, are important for proper ... health. Disruptions of circadian rhythms and sleep-wake cycles have ... study by Douglas Institute researchers unravels a possible basis ... of clock genes in multiple areas of the human ...
... the context of rising levels of cardiovascular disease (CVD) in ... announces that for the first time- the Society will send ... of Cardiology (APCC). The 18th edition of the APCC ... to 8 May 2011. The ESC deputation will present an ...
Cached Medicine News:Health News:University of Houston wins NIH grant for vaccine study 2Health News:University of Houston wins NIH grant for vaccine study 3Health News:Report: California Cities Have Worst Air Pollution in U.S. 2Health News:Report: California Cities Have Worst Air Pollution in U.S. 3Health News:Report: California Cities Have Worst Air Pollution in U.S. 4Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:Anxiety's on the Menu for People With Food Allergies 2Health News:Anxiety's on the Menu for People With Food Allergies 3Health News:Researchers observe disruptions of daily rhythms in Alzheimer's patients' brains 2Health News:The European Society of Cardiology organizes educational program in Asia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: